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Mechanisms of chemoresistance to alkylating agents in
malignant glioma
Abstract
Intrinsic or acquired chemoresistance to alkylating agents is a major cause of treatment failure in
patients with malignant brain tumors. Alkylating agents, the mainstay of treatment for brain tumors,
damage the DNA and induce apoptosis, but the cytotoxic activity of these agents is dependent on DNA
repair pathways. For example, O6-methylguanine DNA adducts can cause double-strand breaks, but this
is dependent on a functional mismatch repair pathway. Thus, tumor cell lines deficient in mismatch
repair are resistant to alkylating agents. Perhaps the most important mechanism of resistance to
alkylating agents is the DNA repair enzyme O6-methylguanine methyltransferase, which can eliminate
the cytotoxic O6-methylguanine DNA adduct before it causes harm. Another mechanism of resistance to
alkylating agents is the base excision repair (BER) pathway. Consequently, efforts are ongoing to
develop effective inhibitors of BER. Poly(ADP-ribose)polymerase plays a pivotal role in BER and is an
important therapeutic target. Developing effective strategies to overcome chemoresistance requires the
identification of reliable preclinical models that recapitulate human disease and which can be used to
facilitate drug development. This article describes the diverse mechanisms of chemoresistance operating
in malignant glioma and efforts to develop reliable preclinical models and novel pharmacologic
approaches to overcome resistance to alkylating agents.
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Abstract
Intrinsic or acquired chemoresistance is a major cause of treatment failure in patients with malignant
brain tumors. Alkylating agents, the mainstay of treatment for brain tumors, damage the DNA and
induce apoptosis, but the cytotoxic activity of these agents is dependent on DNA repair pathways.
For example, O6-methylguanine DNA adducts can cause double-strand breaks, but this is dependent
on a functional mismatch repair (MMR) pathway. Thus, tumor cell lines deficient in MMR are
resistant to alkylating agents. Perhaps the most important mechanism of resistance to alkylating
agents is the DNA repair enzyme O6-methylguanine methyltransferase (MGMT), which can
eliminate the cytotoxic O6-methylguanine DNA adduct before it causes harm. Another mechanism
of resistance to alkylating agents is the base excision repair (BER) pathway. Consequently, efforts
are ongoing to develop effective inhibitors of BER. Poly(ADP-ribose)polymerase (PARP-1) plays
a pivotal role in BER and is an important therapeutic target. Developing effective strategies to
overcome chemoresistance requires the identification of reliable preclinical models that recapitulate
human disease and can be used to facilitate drug development. This manuscript describes the diverse
mechanisms of chemoresistance operating in malignant glioma and efforts to develop reliable
preclinical models and novel pharmacologic approaches to overcome resistance to alkylating agents.
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INTRODUCTION
Intrinsic or acquired resistance to cytotoxic agents remains the greatest obstacle to successful
treatment of human cancer, and a variety of mechanisms of drug resistance have been identified
in human tumors. High-grade malignant gliomas, including glioblastoma (GBM) and
anaplastic astrocytoma, are among the most rapidly growing and devastating cancers. Standard
treatment consists of surgery followed by radiotherapy and chemotherapy with alkylating
agents. Alkylating agents, including carmustine (BCNU), lomustine (CCNU), and
temozolomide, readily cross the blood-brain barrier and have demonstrated the most activity
against malignant glioma. However, despite the ability of these agents to achieve therapeutic
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concentrations in the brain, malignant gliomas are often resistant to alkylating agents.
Identifying and understanding the diverse mechanisms of chemoresistance operating in human
tumors and developing effective strategies to overcome resistance is the focus of ongoing
preclinical and clinical research.
One important mechanism of resistance to alkylating agents is mediated by the DNA repair
enzyme O6-methylguanine methyltransferase (MGMT) (1,2), which repairs O6-alkylguanine
adducts. BCNU and CCNU are bifunctional alkylating agents that form lethal double-strand
crosslinks (3). In contrast, the activity of methylating agents such as temozolomide and
dacarbazine results in persistent O6-methylguanine adducts that initiate futile cycling of the
DNA mismatch repair (MMR) pathway and ultimately causes DNA double-strand breaks and
induction of apoptosis (4,5). The methylation damage induced by these agents can be reversed
by MGMT. Although several studies have shown that a deficiency of MGMT can increase the
sensitivity of high-grade glioma to alkylating agents (6-8), many tumors with low levels of
MGMT are nevertheless chemoresistant (1,2). This suggests that other mechanisms are also
involved in the resistance of some tumors to chemotherapy. For example, deficiency in MMR
can make tumor cells tolerant to mismatched base pairing and mutations in p53, or
overexpression of the anti-apoptotic protein Bcl-2 or Bcl-XL can cause resistance to pro-
apoptotic signals. The base excision repair (BER) pathway can also render alkylating agents
ineffective by repairing other DNA adducts that would otherwise be cytotoxic.
This review will summarize the mechanisms of chemoresistance in malignant glioma and will
focus on the development of agents designed to overcome resistance to alkylating agents, with
particular emphasis on novel molecules designed to inhibit the BER pathway. An important
component of this research involves the development of clinically relevant xenograft models
for testing novel treatment strategies to overcome chemoresistance. Herein, we will describe
a nude mouse serially transplantable xenograft model of GBM that represents an important
tool for testing new agents and treatment strategies.
MECHANISMS OF CHEMORESISTANCE
O6-Methylguanine Methyltransferase
The DNA repair enzyme MGMT appears to play a major role in resistance to temozolomide
and other alkylating agents by removing alkyl groups from the O6 position of guanine (9). The
protective effect of MGMT has been demonstrated in human cell lines (10) and in human
xenograft models (11). For example, studies with MGMT knockout mice revealed that
fibroblasts and bone marrow cells were significantly more sensitive to the toxic effects of
temozolomide than cells from MGMT wild-type mice (12). Moreover, retrovirus-mediated
transfer of the human MGMT gene to cells that are deficient in endogenous MGMT activity
results in high levels of resistance to temozolomide and other alkylating agents (13). In vivo
studies that used mixtures of MGMT-positive and MGMT-negative colon cancer cell lines
injected into nude mice and exposed to BCNU demonstrated that the extent of MGMT
expression in mixed xenografts correlated directly with their sensitivity to BCNU (14).
Xenografts with 0% to 10% MGMT-positive cells were highly sensitive to BCNU and
exhibited a significant growth delay, whereas xenografts with increasing percentages of
MGMT-positive cells grew rapidly in the presence of BCNU (Fig 1) (14). Pretreatment with
a selective MGMT inhibitor, O6-benzylguanine (O6-BG), has been shown to suppress MGMT
activity for approximately 6 hours and sensitize xenografts containing MGMT-positive cells
to BCNU (14). Similarly, other studies showed that inhibition of MGMT with O6-BG promotes
increased antitumor activity of temozolomide both in vitro (15-17) and in vivo (11,18). Thus,
direct removal of O6-methylguanine by MGMT appears to be a major mechanism of resistance
to the cytotoxic effects of alkylating agents.
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In human cancer, the MGMT gene is not commonly inactivated by mutation; loss of MGMT
function is most frequently caused by promoter-region hypermethylation (19,20). Preclinical
studies have shown that methylation of discrete regions of the MGMT promoter is associated
with epigenetic silencing of the gene, loss of MGMT expression (21,22), and diminished DNA
repair activity. Tumors with methylated MGMT promoters are more sensitive to alkylating
agents, whereas tumors with unmethylated MGMT promoters express high levels of the enzyme
and are more resistant to alkylating agents. From a clinical standpoint, MGMT promoter
methylation is associated with improved response to alkylating agents, as evidenced by
improved survival in patients with high-grade gliomas who are treated with BCNU or
temozolomide (23-25). Therefore, MGMT promoter methylation may predict the therapeutic
response to alkylating agents. Several ongoing studies are investigating the correlation between
MGMT methylation status and temozolomide sensitivity. These studies are also investigating
whether increasing the dose intensity of temozolomide treatment can overcome resistance
mediated by MGMT.
Mismatch Repair
The MMR pathway is critical for mediating the cytotoxic effect of O6-methylguanine. The
MMR pathway is comprised of several proteins (hMLH1, hPMS2, hMSH2, hMSH3, and
hMSH6) and is programmed to correct errors in DNA base pairing arising during DNA
replication. Defects in this system cause resistance to temozolomide, presumably because the
cell becomes tolerant to the mispairing of O6-methylguanine with thymine. During DNA
replication, DNA polymerase mispairs O6-methylguanine with thymine, which triggers MMR-
dependent removal of the mispaired thymine. However, the O6-methylguanine remains, and
subsequent mispairing of O6-methylguanine with yet another thymine leads to repetitive
rounds of MMR (15,26,27). It has been proposed that this futile cycling of the MMR system
induces double-strand breaks, which in turn triggers p53-dependent cell cycle arrest and
apoptosis (28). Consequently, tumors that are deficient in MMR are relatively resistant to the
cytotoxic effects of alkylating agents such as temozolomide. In fact, many tumors are known
to be deficient in MMR. For example, hereditary nonpolyposis colon cancer is caused by
mutations in the hMLH1 or hMSH2 genes (29). Therefore, the cytotoxicity of temozolomide
is low in colon cancer cell lines harboring these mutations (30). Deficiency in MMR also occurs
in a number of sporadic human cancers due to methylation of the hMLH1 gene promoter. Of
the 60 cell lines in the National Cancer Institute tumor panel, five are deficient in hMLH1
activity, and these cell lines are all resistant to temozolomide (31).
Poly(ADP-ribose)polymerase
Another important mechanism of resistance to alkylating agents is the BER pathway, which is
thought to be involved in repair of N7-methylguanine and N3-methyladenine DNA adducts.
These are the most common DNA adducts created by temozolomide, accounting for
approximately 90% of all methylation events. Poly(ADP-ribose)polymerase (PARP-1) plays
a pivotal role in the BER pathway. This enzyme is activated by DNA strand breaks and is
expressed at high levels in most human cell lines. This led to the investigation of PARP
inhibitors as a means of increasing the cytotoxic activity of temozolomide. Inhibition of BER
would be expected to increase the cytotoxicities of N7-methylguanine and N3-methyladenine
lesions, which are otherwise readily repaired in most normal cells and tumor cells with an intact
BER pathway. In particular, PARP inhibitors would be expected to dramatically enhance the
cytotoxicity of temozolomide in MMR-deficient cells because these cells tolerate O6-
methylguanine DNA adducts (32).
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Apoptosis-Regulating Genes
In addition to the resistance mechanisms described above that involve DNA repair,
chemoresistance in gliomas may be influenced by dysregulation of apoptosis-regulating genes
and proteins. For example, loss of normal p53 function, up-regulation of Bcl-2 or Bcl-XL, or
overexpression of epidermal growth factor receptor (EGFR) can disrupt the normal apoptotic
response to DNA damage. It is well known that p53 plays a central role in detecting DNA
damage and regulating the signaling pathways required to mediate apoptosis. Murine tumors
deficient in Trp53 (the gene that encodes p53 in mice) and cell lines that express mutant
Trp53 are less sensitive to gamma-irradiation or chemotherapy (33). Reintroduction of wild-
type Trp53 by adenoviral transfer restores sensitivity to cytotoxic agents resulting in apoptosis
and suppression of tumor growth in nude mice (34,35). Wild-type p53 interacts with the
promoters of a variety of genes, including EGFR, MDM2, and Bcl-2. Wild-type p53 increases
transcriptional activity of the EGFR and MDM2 genes and represses transcription of Bcl-2
(36). Based on the analysis of patient tumor samples, inactivation of p53 occurs in more than
50% of primary GBMs, and this is associated with up-regulation of Bcl-2 (15,37,38). Consistent
with these findings, up-regulation of either Bcl-2 or EGFR expression in glioma cell lines has
been correlated with drug resistance and decreased apoptotic response in vitro (39,40).
EGFR is the most frequently amplified and mutated oncogene in de novo malignant glioma,
and several clinical as well as histopathologic studies have suggested that the presence of
EGFR amplification might affect the response of malignant gliomas to chemotherapy (41). In
one study, overexpression of a tumor-derived mutant form of EGFR known as variant III
(EGFRvIII) in wild-type p53-expressing human glioma cells resulted in resistance to cisplatin
(39). The mechanism involved was suggested to be suppression of drug-induced apoptosis,
which was largely mediated by increased expression of Bcl-XL and subsequent inhibition of
caspase-3–like protease activation. Although dysregulated expression of EGFR, MDM2, and
Bcl-2 frequently occurs in GBM, none of these changes in gene expression has been clearly
identified as an independent prognostic factor for either the biologic behavior of gliomas or
patient survival (42). Additional studies into the mechanisms regulating apoptosis and
sensitivity to DNA damage may reveal new strategies for overcoming the resistant phenotype
of GBM.
Given the important role of temozolomide in the treatment of gliomas and the probable
dependence of its activity on MGMT activity, a recent study has sought to better characterize
the molecular pathways mediating temozolomide cytotoxicity in human malignant glioma cell
lines in terms of MGMT, Bcl-2, and p53 expression (40). This study showed that forced
expression of Bcl-XL protein attenuates temozolomide cytotoxicity in MGMT-negative
LNT-229 cells but not in MGMT-positive LN-18 cells. Neither irradiation nor dexamethasone
modulated MGMT activity or temozolomide sensitivity in this paradigm. Abrogation of p53
wild-type function with RNA interference or expression of a dominant-negative p53 mutant
also conferred resistance to temozolomide. Conversely, agents such as CP-31398 that stabilize
the wild-type conformation of p53 sensitize glioma cells to temozolomide (43). These data
suggest that wild-type p53 activity is necessary for sensitivity to alkylating agents. Further,
since low-grade gliomas have a high incidence of p53 mutations, they may be less sensitive to
temozolomide. However, these conclusions are limited by the preclinical paradigm applied
and may not accurately reflect the clinical situation.
Transporter Proteins
Molecular transporter proteins that actively expel chemotherapeutic drugs from tumor cells
have been implicated in resistance to chemotherapy, and this may be another mechanism that
could result in resistance to temozolomide (44). The two transporters commonly associated
with drug resistance in cancer cells are the MDR1 gene products P-glycoprotein and the
multidrug resistance-associated protein (45). Multidrug resistance-associated protein
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overexpression has been shown to have a direct effect on the response of neuroblastomas to
chemotherapy and to be associated with poor clinical outcome (46). The role of these drug
transporters in resistance to alkylating agents in gliomas is an area of active interest.
PRECLINICAL MODELS TO TEST STRATEGIES TO OVERCOME
CHEMORESISTANCE
Efforts to develop new strategies to overcome chemoresistance underscore the need for reliable
preclinical models to test these strategies. Ideally, robust preclinical models would facilitate
the development of optimal therapeutic regimens so that only the most effective treatment
regimens are moved forward into clinical testing. These model systems could be used to
develop predictive markers for treatment response that would guide the development of new
agents or individualized therapies, thereby minimizing patients' exposure to ineffective
treatment approaches.
Cell Culture Models
Several cell culture models have been used to demonstrate the role of MGMT in resistance to
temozolomide. For example, studies with Chinese hamster ovary cells lacking endogenous
MGMT expression have demonstrated that overexpression of MGMT confers resistance to
temozolomide (47). Similarly, established glioma cell lines have provided a model for studying
the correlation between MGMT levels and sensitivity to various alkylating agents (10).
Although cell culture models are valuable for the design of cancer therapies, these models do
not consistently predict tumor response to cytotoxic or biologic agents in the clinical setting.
Cultured cell lines do not necessarily reflect the biology or heterogeneity of primary tumors
nor their therapeutic response to treatment and may have less relevance in the clinical setting
than in vivo models.
Transgenic Mouse Models
Transgenic mouse models are genetically defined animal models that allow for testing of
therapies that are targeted specifically at the affected pathways (48). For example, transgenic
mice have been engineered to recapitulate key genetic features of GBM such as mutant
EGFR; such mice are excellent for the evaluation of specific molecular mechanistic questions.
However, because of limited genetic diversity, these models may be less useful for identifying
the multiple mechanisms of sensitivity and resistance found in the spectrum of genetically
diverse tumors found in patients.
Xenograft Models
In xenograft models, established cell lines are often grown as subcutaneous flank (heterotopic)
or intracranial (orthotopic) tumors. However, orthotopic xenografts created from established
GBM cell lines generally fail to recapitulate the infiltrative growth pattern of primary human
GBM; instead, they tend to form solid masses at the injection site, compressing rather than
invading the parenchyma (49-52). In addition, growth of tumor cell lines in culture can lead
to a high degree of selection, causing the loss of important gene alterations that are common
among primary GBMs such as EGFR gene amplification (53,54). Glioblastoma cell lines
established from primary tumors with amplified EGFR and/or EGFR mutations invariably lose
this amplification and mutation through prolonged cell culture. This observation suggests that
the growth advantage associated with increased EGFR expression and the constitutively active
mutant form of the receptor (eg, EGFRvIII) is specific to the in vivo environment and that
high-level EGFR signaling may in fact be a disadvantage for in vitro tumor cell growth (53,
54). Although the use of heterotopically grown cell lines offers some insight into tumor biology,
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prolonged selection of these cell lines in cell culture limits their clinical relevance for
understanding patient tumor responsiveness to chemotherapeutic or biologic agents.
Recently, the amenability of a serially transplantable nude mouse xenograft model was
indicated for testing novel therapeutics and for answering key biologic and clinical questions
regarding mechanisms of resistance, drug dosing, and combination strategies (55,56). In this
model (Fig 2), GBM tissue samples are obtained from patients and serially propagated in the
flank of athymic nude mice. This method of propagation allows preservation of key
morphologic and histopathologic features, such as the presence of necrosis, similar to those of
the primary GBMs from which they were derived (Fig 3). By establishing and maintaining
multiple GBM xenografts in this manner, a genetically diverse panel of GBM tumors is
available for testing novel therapeutic strategies.
With the test panel approach, therapies are routinely evaluated against intracranial tumors that
are established from short-term cultures of freshly resected flank tumors. Single-cell
suspensions are stereotactically injected into the brains of nude mice (Fig 2), and this results
in a nearly 100% rate of successful engraftment. Analysis of the resulting intracranial tumors
shows that these tumors maintain key histopathologic features of the original tumor, such as a
highly invasive growth pattern and nuclear pleomorphism (Fig 4). Therefore, it is expected
that the chemosensitivity of the serially propagated human tumor likely would be comparable
to that of the patient tumor from which it was derived and that this model would predict the
activity of chemotherapies used alone or in combinations. Indeed, MGMT promoter
methylation is faithfully maintained from the original patient tumor specimen. Among a panel
of xenografts developed at the Mayo Clinic, the proportion of xenografts that exhibit MGMT
promoter methylation (approximately 45%) is similar to that reported in series of primary
tumors (24). In contrast, 80% of GBM cell lines have a methylated MGMT promoter. This
xenograft model demonstrates that primary human GBMs, which are propagated in the flank
and transplanted orthotopically, closely resemble the human microenvironment, particularly
in relation to growth characteristics and invasive properties.
PARP INHIBITORS
There is considerable interest in modulating the activity of PARP-1 in the clinical setting both
for the treatment of cancer and nonmalignant diseases. Potential applications in the
nonmalignant setting have recently been reviewed (57,58). In the realm of cancer therapy,
preclinical models have shown that inhibition of PARP-1 can potentiate the activity of both
radiotherapy and a variety of chemotherapeutic agents (59-65), and PARP-1 inhibitors have
also demonstrated single-agent activity against certain tumor cell lines (66,67). These
observations have stimulated considerable interest in these agents as anticancer therapy.
AG-14361 is a potent inhibitor of PARP-1 with an inhibition constant in the nanomolar range,
and AG-014699, a potent tricyclic indole with an inhibition constant of < 5 nM, is a close
analogue and the first PARP inhibitor to enter clinical trials in cancer patients (68). AG-014699
was developed through a collaborative program between the University of Newcastle upon
Tyne, UK, and Pfizer.
The effects of AG-14361 on the cytotoxicity of temozolomide were studied using two
genetically matched cell lines; the parent cell line was MMR deficient, and the matched cell
line was MMR proficient by virtue of the transfer of chromosome 3 (69). As expected,
AG-14361 enhanced temozolomide cytotoxicity in both MMR-proficient and MMR-deficient
cell lines, but the degree of enhancement was greater in the MMR-deficient cell lines (3.7- to
5.2-fold increase compared with only a 1.5- to 3.3-fold increase in the MMR-proficient cell
lines). The enhanced potentiation of temozolomide activity in MMR-deficient cells compared
with MMR-proficient cells suggests that it might be possible to selectively enhance the
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antitumor activity of temozolomide in the clinical setting using a PARP inhibitor because
normal tissue (particularly the hematopoietic system) would be MMR proficient, whereas
tumors may be MMR deficient. Although, as with any agent that enhances the cytotoxic
potential of a chemotherapy drug, addition of a PARP inhibitor may cause significant added
toxicity. The phase I study with AG-014699 demonstrated that a normal dose of temozolomide
could be safely administered in combination with a PARP inhibitor (70). However, in the phase
II study in patients with metastatic melanoma, a significant proportion of patients required a
25% reduction of the temozolomide dose or treatment delays because of myelosuppression
(71).
The phase I trial of AG-014699 in combination with temozolomide for the treatment of solid
tumors (primarily metastatic melanoma) was divided into two parts (70). The first part of the
study was designed with a pharmacodynamic endpoint to demonstrate significant (at least 50%)
PARP inhibition in peripheral blood lymphocytes 24 hours after the first dose of AG-014699.
Temozolomide 100 mg/m2 (50% of the standard dose) was given in combination with
AG-014699 (escalating doses from 1 to 12 mg/m2) daily for 5 days every 28 days. The reduced
dose of temozolomide was initially used in the event that inhibition of PARP potentiated the
known myelosuppressive effects of temozolomide. Significant inhibition of PARP-1 was
demonstrated at all dose levels investigated. Inhibition was profound and sustained for 24 hours
at doses > 8 mg/m2 (Fig 5). Moreover, the combination of 12 mg/m2 AG-014699 with 100 mg/
m2 temozolomide was not toxic. In the second part of the study, patients with metastatic
melanoma (exclusively) were treated with 12 mg/m2 AG-014699 and escalating doses of
temozolomide. All patients consented to tumor biopsies to allow assessment of target tissue
PARP inhibition. During this part of the study, it was possible to administer a full dose of
temozolomide (200 mg/m2) with 12 mg/m2 AG-014699 without additional toxicity being
observed while achieving significant tumor PARP inhibition (∼60% below baseline activity)
in tumor tissue 5 hours after dosing. The 5-hour time point was selected because at that time
temozolomide is known to cause maximum DNA strand breaks (72); this would be the optimal
time to have maximal PARP inhibition in order to achieve effective chemopotentiation.
Maximum PARP inhibition in tumor biopsies has been observed with the highest dose of
AG-014699 investigated (18 mg/m2); however, this dose also enhanced the myelosuppressive
effects of temozolomide, leading to dose reductions and delays.
The encouraging PARP inhibition observed in this phase I study provided the rationale for a
phase II study of the combination of AG-014699 and temozolomide in patients with metastatic
melanoma. Forty-six patients were treated with temozolomide (200 mg/m2) and AG-014699
(12 mg/m2) daily for 5 days every 28-day cycle (71). This study confirmed that temozolomide
can be administered in the presence of a PARP inhibitor with only minor dose reductions being
required because of hematologic toxicity; 18 (39%) patients required a dose reduction of
temozolomide to 150 mg/m2. Moreover, this study met its primary objective (ie, an increase
in the response rate compared with historical data with temozolomide alone), and this
combination also appears to improve time to progression.
Other PARP-1 inhibitors are now entering early clinical development in a range of malignant
indications. For example, there are plans for INO-010 to enter clinical studies in combination
with temozolomide both in patients with metastatic melanoma and in patients with malignant
glioma (Slazman A, personal communication, PARP2005 conference). Although PARP
inhibitors for clinical use were initially developed as chemo-potentiating agents, contemporary
data suggest a role for single-agent treatment with a PARP inhibitor in tumors that are deficient
in homologous recombination repair. It has recently been shown that cells homozygous for
nonfunctional BRCA1 or BRCA2 are exquisitely sensitive to PARP inhibitors (67,73). BRCA1
and BRCA2 are involved in homologous recombination repair, leading to the hypothesis that
single-strand breaks that accumulate due to inhibition of PARP are converted to double-strand
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breaks during DNA replication, which, in the absence of homologous recombination repair,
cannot be corrected and thus lead to apoptosis. This observation was made independently by
two different groups using different PARP inhibitors and model cell lines, suggesting that this
sensitivity is indeed because of PARP inhibition rather than any other phenomenon. Inherited
mutations in BRCA1 and BRCA2 are associated with a very high lifetime risk of breast and
ovarian cancer and may also be etiologic in some cases of prostate and pancreatic cancer. An
orally available PARP inhibitor KU-0059436 (KuDOS, AstraZeneca) is in phase I
development and has shown a suggestion of antitumor activity in BRCA defective tumors
(74). A formal phase II study of AG-014699 in familial breast and ovarian cancer is also
planned. Furthermore, suppression of BRCA protein expression because of promoter
methylation has been reported, suggesting that some spontaneous malignancies may also be
deficient in homologous recombination repair as a result of epigenetic gene silencing (75).
Other acquired defects affecting homologous recombination repair have also been reported in
human tumors and would be expected to confer sensitivity to PARP inhibitors (76,77).
CONCLUSIONS AND FUTURE DIRECTIONS
In recent years, our understanding of the pathways responsible for repairing DNA damage and
rendering cancer cells resistant to chemotherapy has greatly improved; consequently, effective
strategies to modulate clinical resistance to cytotoxic agents are evolving. DNA damage caused
by temozolomide is repaired by BER, removed by MGMT, or tolerated in MMR-deficient
cells. Modulation of the first two pathways of resistance is now becoming a clinical possibility.
Early clinical trials with MGMT inhibitors such as O6-BG have been completed (reviewed by
Hegi et al in this supplement), and this article reviews the promising initial results of trials
investigating modulation of temozolomide resistance with PARP-1 inhibitors. Inhibition of
PARP activity would, in addition, allow PARP inhibitors to act as radiopotentiators because
the DNA damage caused by radiotherapy consists of single- and double-strand breaks (63).
Repair of both types of lesions is known to involve recruitment of PARP-1 (78). Therefore,
the use of a potent PARP inhibitor as part of multimodality therapy with temozolomide and
radiotherapy in patients with GBM may have particular clinical relevance and might
significantly improve therapeutic benefit in this group of patients.
Developing effective treatment regimens is a major challenge in malignant glioma, and
identification of a reliable preclinical model that could recapitulate human disease would
facilitate this process. The murine serially transplantable xenograft model is simple and
reproducible and maintains most of the characteristics of primary human GBM. This model
preserves the molecular phenotype and invasiveness of GBM xenografts, which is critical for
investigating molecularly targeted agents. The combination of flank tumor genetic
characterizations with a procedure for initiating intracranial xenografts makes this model an
invaluable tool for multiple neuro-oncology research applications. The versatility and
applicability of this preclinical model will contribute to the elucidation of the molecular
mechanisms of chemoresistance, which should ultimately result in the identification of more
effective therapeutic strategies for malignant glioma.
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Fig 1.
Growth of tumor xenografts containing various percentages of O6-methylguanine
methyltransferase-positive cells (indicated by numbers above each curve) in animals treated
with 23 mg/kg bischloroethyl nitrosourea (BCNU). Adapted with permission from Phillips et
al, Cancer Res 57:4817-4823, 1997 (14).
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Fig 2.
Methodology for generating a murine serially transplantable xenograft model. Human
glioblastomas are propagated in the flank of mice and then briefly cultured in vitro before
stereotactic injection into the brains of nude mice.
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Fig 3.
Morphology and histopathology of glioblastomas grown in the flank. Flank tumors
recapitulated human tumor morphology as evidenced by the presence of (A) high cellularity
and mitotic activity (arrows) and (B) necrosis (closed arrows) and vascular endothelial
proliferation (open arrows).
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Fig 4.
Growth of intracranial tumors established from flank xenografts. A representative section of
an orthotopic tumor displays a close resemblance to primary tumors regarding advanced stage
of growth. The tumor revealed high cellularity (open arrow) and invasion into corpus callosum
(closed arrow).
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Fig 5.
Pattern of ex vivo PARP inhibition observed in PBLs from patient treated with a PARP
inhibitory dose of AG-014699 27.8 mg (12 mg/m2). Abbreviations: PAR, poly(ADP)-ribose;
PBL, peripheral blood lymphocytes.
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